scholarly journals Heat Shock Protein 70, Released from Heat-Stressed Tumor Cells, Initiates Antitumor Immunity by Inducing Tumor Cell Chemokine Production and Activating Dendritic Cells via TLR4 Pathway

2009 ◽  
Vol 182 (3) ◽  
pp. 1449-1459 ◽  
Author(s):  
Taoyong Chen ◽  
Jun Guo ◽  
Chaofeng Han ◽  
Mingjin Yang ◽  
Xuetao Cao
Keyword(s):  
Dendritic Cells ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Heat Shock Protein 70 ◽  
Antitumor Immunity ◽  
Chemokine Production

Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity

2002 ◽  
Vol 84 (2) ◽  
pp. 81-87 ◽  
Author(s):  
Xiaohong Chen ◽  
Qun Tao ◽  
Hai Yu ◽  
Lihuang Zhang ◽  
Xuetao Cao
Keyword(s):  
Heat Shock ◽  
Cell Membrane ◽  
Heat Shock Protein ◽  
Tumor Cell ◽  
Heat Shock Protein 70 ◽  
Antitumor Immunity ◽  
Tumor Cell Membrane ◽  
Membrane Bound

scholarly journals Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

Blood ◽  
2007 ◽  
Vol 109 (11) ◽  
pp. 4839-4845 ◽  
Author(s):  
Radek Spisek ◽  
Anna Charalambous ◽  
Amitabha Mazumder ◽  
David H. Vesole ◽  
Sundar Jagannath ◽  
...  
Keyword(s):  
Cell Death ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Antitumor Immunity ◽  
Heat Shock Protein 90 ◽  
Human Tumors ◽  
Tumor Cell Death ◽  
Dying Cells

Abstract Most anticancer chemotherapies are immunosuppressive and induce nonimmunogenic tumor cell death. Bortezomib, a specific inhibitor of 26S proteasome, has shown clinical activity in several human tumors, including myeloma. Here we show that the uptake of human myeloma cells by dendritic cells (DCs) after tumor cell death by bortezomib, but not γ irradiation or steroids, leads to the induction of antitumor immunity, including against primary tumor cells, without the need for any additional adjuvants. The delivery of activating signal from bortezomib-killed tumor cells to DCs depends on cell-cell contact between DCs and dying tumor cells and is mediated by bortezomib-induced exposure of heat shock protein 90 (hsp90) on the surface of dying cells. The combination of bortezomib and geldanamycin (an hsp90 inhibitor) leads to greater apoptosis of tumor cells but abrogates their immunogenicity. These data identify drug-induced exposure of endogenous heat shock proteins on the surface of dying cells as a mechanism of immunogenic death of human tumors. Specific targeting of bortezomib to tumors may enhance their immunogenicity and the induction of antitumor immunity.

scholarly journals Human recombinant heat shock protein 70 affects the maturation pathways of dendritic cells in vitro and has an in vivo adjuvant activity

2008 ◽  
Vol 84 (1) ◽  
pp. 199-206 ◽  
Author(s):  
Barbara Valentinis ◽  
Annalisa Capobianco ◽  
Francesca Esposito ◽  
Alessandro Bianchi ◽  
Patrizia Rovere-Querini ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Heat Shock Protein 70 ◽  
Adjuvant Activity
Sign in / Sign up

Export Citation Format

Share Document